Top

Cancer Chemotherapy and Pharmacology

Published in:

01-08-2011 | Original Article

Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity

Authors: Muhittin A. Serdar, Erdim Sertoğlu, Metin Uyanık, Serkan Tapan, Okhan Akın, Murat Cihan

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2011

Abstract

Purpose

5-Fluorouracil (5-FU), acting as a pyrimidine antagonist, is a major chemotherapy drug used for the treatment of tumors such as gastrointestinal, breast, ovary, and head and neck cancers. The key and rate-limiting enzyme in 5-FU catabolism is dihydropyrimidine dehydrogenase (DHPDH), whose partial or complete deficiency exposes to a severe 5-FU toxicity in patients. The determination of DHPDH activity in patients before the treatment and setting up a personalized therapy for each patient receiving the drug can help us to prevent the possible risk of toxicity.

Methods

To isolate peripheral blood mononuclear cells (PBMCs), EDTA-anticoagulated blood samples were collected from randomly selected 47 patients and examined for 5-FU and its metabolite dihydrofluorouracil (FUH2) by using a liquid chromatography–tandem mass spectrometry (LC–MS/MS) to observe DHPDH activity at different intervals (0 and 4th hour) indirectly.

Results

Intra-assay and interassay CV % values of samples from the measurements of the modified methods are found 1.3–11.9, 2.3–9.4 for 5-FU and 3.1–14.4, 3.3–12.6 for FUH2, respectively. The reference values derived from 45 patients treated with 5-FU are 1.84 ± 0.34 ug/gr protein for 5-FU, 40.15 ± 11.43 ng/gr protein for FUH2, respectively. FUH2/5-FU ratio is 21.9 ± 3.72. In addition, the results determined from two patients, in which the lack of DHPDH is considered, were 3.24 and 4.16 ug/gr protein for 5-FU, 4.1 and 6.7 ng/gr protein for FUH2. FUH2/5-FU ratio is 1.26 and 1.61.

Conclusion

The measurements of 5-FU, FUH2, and especially their ratio (FUH2/5-FU) by the modified LC–MS/MS method could be used to determine DHPDH enzyme activity.

Hiroyuki B, Kenichi T, Toru K et al (2003) Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol 52:469–476CrossRef

Lostia AM, Lionetto L, Ialongo C, Gentile G, Viterbo A, Malaguti P, Paris I, Marchetti L, Marchetti P, De Blasi A, Simmaco M (2009) A liquid chromatography–tandem mass spectrometry method for the determination of 5-fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit 31:482–488PubMedCrossRef

Miyazaki K, Shibahara T, Sato D et al (2006) Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol 41:140–150PubMedCrossRef

Deporte-Fety R, Picot M, Amiand M et al (2001) High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. J Chromatogr B Biomed Sci Appl 762:203–209PubMedCrossRef

Van Kuilenburg ABP, Klumpen HJ, Westermann AM et al (2007) Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. Eur J Cancer 43:459–465PubMedCrossRef

Guimbaud R, Guichard S, Dusseau C et al (2000) Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans. Cancer Chemother Pharmacol 45:477–482PubMedCrossRef

Milano G, Chamorey AL (2002) Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 19:177–189PubMedCrossRef

Di Paolo A, Ibrahim T, Danesi R et al (2002) Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Ther Drug Monit 24:588–593PubMedCrossRef

Ridge SA, Sludden J, Wei X et al (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer 77:497–500PubMedCrossRef

10.

Lu ZH, Zhang RW, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433–5438PubMed

11.

Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248–2253PubMed

12.

McMurrough J, McLeod HL (1996) Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 41:425–427PubMedCrossRef

13.

Meta-Analysis Group In Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16(11):3537–3541

14.

Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006–2011PubMed

15.

Van Kuilenburg AB, Haasjes J, Richel DJ et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DHPDH) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DHPDH gene. Clin Cancer Res 6:4705–4712PubMed

16.

Omura K (2003) Clinical implications of dihydropyrimidine dehydrogenase (DHPDH) activity in 5-FU based chemotherapy: mutations in the DHPDH gene, and DHPDH inhibitory fluoropyrimidines. Int J Clin Oncolology 8:132–138CrossRef

17.

Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Hoffken K (2001) Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DHPDH) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7:2832–2839PubMed

18.

Etienne MC, Chatelut E, Pivot X et al (1998) Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 34:92–97PubMedCrossRef

19.

Van Kuilenburg AB, van Lenthe H, Blom MJ, Mul EP, Van Gennip AH (1999) Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 79:620–626PubMedCrossRef

20.

Furuhata T, Kawakami M, Okita K, Kimura Y, Kihara C, Tsuruma T, Ohnura T, Yamaguchi K, Hata F, Katsuramaki T, Sasaki K, Hirata K (2006) Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients. J Exp Clin Cancer Res 25:79–82PubMed

21.

Milano G, Etienne MC, Pierrefite V et al (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627–630PubMedCrossRef

22.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275PubMed

23.

Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197–201PubMed

24.

Terashima M, Irinoda T, Kawamura H et al (2003) Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1–5 for gastric cancer, and its pharmacologic and kinetic rationale. Cancer Chemother Pharmacol 51:240–246PubMed

25.

Van Kuilenburg ABP, Van Lenthe H, Tromp A et al (2000) Pitfalls in the diagnosis with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 46:9–17PubMed

26.

Johnson MR, Yan J, Shao L, Albin N, Diasio RB (1997) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DHPDH) activity. Screening cancer patients for DHPDH deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 696:183–191PubMedCrossRef

27.

Ogura K, Ohnuma T, Minamide Y, Mizuno A, Nishiyama T, Nagashima S, Kanomaru M, Hiratsuka A, Watabe T, Uenmatsu T (2005) Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations. Clin Cancer Res 11:5104–5111PubMedCrossRef

28.

Jiang W, Lu Z, He Y, Diasio RB (1997) Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3:395–399PubMed

29.

Kouwaki M, Hamajima N, Sumi S, Nonaka M, Ssaki M, Dobashi K, Kidouchi K, Togari H, Wada Y (1998) Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-Fluorouracil toxicity. Clin Cancer Res 4:2999–3004PubMed

30.

Sumi S, Kidouchi K, Hayashi K, Imaeda M, Asai M, Wada Y (1998) Urinary screening for pyrimidine metabolism disorders: reference ranges for dihydrouracil, uracil, and dihydroduracil/uracil ratio. Adv Exp Med Biol 431:191–195PubMed

31.

Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB (2004) Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2–13C-uracil breath test. Clin Cancer Res 10:2653–2658CrossRef

32.

Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB (2006) The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 plasma [2–13C] dihydrouracil. Clin Cancer Res 15:549–555CrossRef

Title: Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity
Authors: Muhittin A. Serdar
Erdim Sertoğlu
Metin Uyanık
Serkan Tapan
Okhan Akın
Murat Cihan
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1528-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2011

The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention

Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells

Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX

Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling

A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer

Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer